By Monica Heger
This story, originally published Dec. 16, has been updated to include information about Sequenom's customers.
Two months after the launch of its non-invasive MaterniT21 test for Down syndrome, Sequenom said that a journal has accepted a study demonstrating the use of its sequencing-based approach for diagnosing trisomy 13 and 18.
Sequenom expects that the paper will be published in the first quarter of 2012.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
